anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

47,221-47,280 of 319,975

filter-aware
01
Slide 1
2023.05.31 Bernstein Conference2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
02
2023.05.31 Bernstein Conference2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
03
The slide uses a chevron-based timeline to illustrate strategic evolution.2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
04
The slide uses a 3x3 grid structure to present key performance indicators.2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
05
Uses a 'From... To...' comparison framework.2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
06
The chart tracks performance over rolling three-year periods from 2016-2018 through 2020-2022, with a final column indicating the most recent performance exceeding the $1Tn target.2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
07
The slide uses a simple three-column layout to present high-level strategic targets.2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
08
2023.05.31 Bernstein Conference2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
09
The chart uses a waterfall structure to bridge the gap between current and future assets.2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
10
The slide uses a classic waterfall bridge structure to explain the delta between current and future financial performance.2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
11
2023.05.31 Bernstein Conference2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
12
This slide provides technical definitions for terms like WM Client Assets, Fee-Based Assets, Client Relationships, NNA, and peer comparison methodology.2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
13
2023.05.31 Bernstein Conference2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
14
2023.05.31 Bernstein Conference2023.05.31 Bernstein Conference · Morgan Stanley
Consulting deck Equity research 1 hit
181
This is a standard regulatory disclosure document.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
182
This is a standard legal disclosure page from an ERISA or investment advisory presentation.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
183
This is a standard legal disclosure page, likely part of a larger document set.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
01
Slide 1
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
02
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
03
The slide uses a list of callout boxes to highlight key company milestones and financial status.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
04
The slide uses a timeline-based visualization to show the status of drug development programs.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
05
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
06
The slide uses a horizontal process-like flow to present key metrics.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
07
The slide emphasizes the bioerodible nature and small size of the insert compared to legacy technology.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
08
The slide explains the mechanism of action (Vorolanib) and the delivery technology (Durasert E) for the product DURAVYU.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
09
The slide uses a table-like structure to map clinical trials (DAVIO, DAVIO 2, PAVIA, VERONA) to patient counts and key outcomes.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
10
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
11
The slide uses a four-column layout to present strategic advantages.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
12
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
13
Includes a callout box regarding LUGANO enrollment status.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
14
The slide uses a timeline framework to track trial progress from Jan 2025 to mid-2026.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
15
Includes company logo and copyright information.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
16
The slide uses a timeline-based visual to contrast injection frequency across five different pharmaceutical products.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
17
The slide uses a timeline-based study design framework.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
18
The slide uses a split-layout with a summary/thesis on the left and specific trial results on the right.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
19
The chart compares DURAVYU 2.7mg, 1.3mg, and aflibercept 2mg. A red box highlights the early improvement at Week 4.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
20
The outlier patient missed multiple visits, leading to significant vision loss at week 24.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
21
The chart compares DURAVYU 2.7mg, DURAVYU 1.3mg, and Aflibercept 2mg. The final values at Week 24 are highlighted in a box.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
22
Includes company logo and copyright/disclaimer footer.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
23
Supplement-free is defined as patients who did not receive a supplement at any point during the study.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
24
The slide uses a timeline to show the transition from standard-of-care anti-VEGF injections to the DURAVYU treatment.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
25
The slide uses a timeline to show prior SOC injections followed by the DURAVYU treatment and subsequent follow-up.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
26
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
27
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
28
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
29
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
01
Slide 1
Goldman Sachs Presentation FinalGoldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Attention1 hit
02
Goldman Sachs Presentation FinalGoldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Attention1 hit
03
The slide uses a three-column layout to categorize business operations by geographic scope (Regional, National, International) with corresponding maps.Goldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · NeedLoop · Logic Chain1 hit
04
U.S. Bancorp is highlighted in each column to show its relative rank.Goldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · NeedLoop · Logic Chain1 hit
05
The slide uses a pie chart to illustrate the revenue contribution of four main business lines.Goldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · NeedLoop · Logic Chain1 hit
06
Goldman Sachs Presentation FinalGoldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Satisfaction1 hit
07
Includes data tables for volume composition and line charts for monthly sales volume growth relative to 2019.Goldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Satisfaction1 hit
08
Goldman Sachs Presentation FinalGoldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Satisfaction1 hit
09
Includes two pie charts for relationship segmentation and a bar chart for talech customer growth.Goldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Satisfaction1 hit
10
The slide uses a split-screen comparison layout to showcase two distinct product offerings.Goldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Satisfaction1 hit
11
Goldman Sachs Presentation FinalGoldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Satisfaction1 hit
12
Includes pro-forma financial charts comparing USB standalone vs combined entity, and a table of branch footprints.Goldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Satisfaction1 hit
13
The slide uses an ESG framework to categorize corporate responsibility efforts.Goldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · Satisfaction1 hit
14
Goldman Sachs Presentation FinalGoldman Sachs Presentation Final · U.S. Bancorp
Consulting deck Equity research Beat · SatisfactionLoop · Why Now1 hit